OS Therapies Announces Positive Data From The Study Of OST-HER2 In Osteosarcoma In Dogs

(RTTNews) - OS Therapies Inc. (OSTX) Thursday announced positive data for OST-HER2 in combination with palliative radiation in dogs with unresected appendicular osteosarcoma.

Results from the study showed clinical and radiographic arrest of the primary tumor, delayed pulmonary metastases and prolonged overall survival of more than than 500 days in 5 out of 15 dogs.

"Based upon this initial research, OS Therapies conducted a successful translational Phase 2b clinical trial in the rare pediatric indication of prevention of recurrence of fully resected, osteosarcoma lung metastases. Our newly published canine data and unpublished radiation combination canine data expands the potential use of OST-HER2 into delay/prevention of metastasis and PFS following resected primary osteosarcoma and raises the intriguing possibility of combination radiation therapy and OST-HER2 in the treatment of unresectable osteosarcoma," said Nicola Mason, the Paul A. James and Charles A. Gilmore Endowed Professor at the University of Pennsylvania, School of Veterinary Medical.

The company intends to submit this data to USDA along with new data generated on its newly patented, commercially superior manufacturing process, to gain conditional approval for the new manufacturing process for OST-HER2 in the U.S. to begin sales in 2025. OS Therapies also plans to conduct a pivotal study to get full approval in 2026.